Differences in telomerase activity between colon and rectal cancer

Canadian Journal of Surgery

Volumn 57, Issue 3, 2014, Pages 199-208

  Ayiomamitis, Georgios D ^a,b   Notas, George ^a   Zaravinos, Apostolos ^a   Zizi Sermpetzoglou, Adamantia ^b   Georgiadou, Maria ^a   Sfakianaki, Ourania ^a   Kouroumallis, Elias ^a,c  

^a UNIVERSITY OF CRETE   (Greece)

^b TZANEIO GENERAL HOSPITAL OF PIRAEUS   (Greece)

^c UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

MLH1 PROTEIN, HUMAN; NUCLEAR PROTEIN; PROTEIN P53; SIGNAL TRANSDUCING ADAPTOR PROTEIN; TELOMERASE; TUMOR MARKER;

ADENOCARCINOMA; AGED; ARTICLE; COLON TUMOR; COMPARATIVE STUDY; DISEASE COURSE; ENZYMOLOGY; FEMALE; FOLLOW UP; GENETICS; HUMAN; KAPLAN MEIER METHOD; MALE; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; PROSPECTIVE STUDY; REAL TIME POLYMERASE CHAIN REACTION; RECTUM TUMOR; SURVIVAL RATE; VERY ELDERLY;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADENOCARCINOMA; AGED; AGED, 80 AND OVER; COLONIC NEOPLASMS; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NUCLEAR PROTEINS; PROGNOSIS; PROSPECTIVE STUDIES; REAL-TIME POLYMERASE CHAIN REACTION; RECTAL NEOPLASMS; SURVIVAL RATE; TELOMERASE; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84904321295     PISSN: 0008428X     EISSN: 14882310     Source Type: Journal    
DOI: 10.1503/cjs.031312     Document Type: Article

References (56)

1. Bufill JA. Colorectal cancer evidence for distinct genetic categories based on proximal or distal mmor location.Ann Intern Med 1990;1 13: 779-88.
2. Oh SW, Kim YR, Choi YS, et al. The comparison of the risk factors and clinical manifestations of proximal and distal colorectal cancet Dis Colon Rectum 2008;51: 56-61.
3. Gurvaz P, Buchur P, Nuyruud-Caspar I, ut al. Pruximal lucatiun uf colon cancer is a risk factor for development of metachronous colorectal cancer: A population-based smdy. Div Colon Rectum 2005;48: 227-32.
4. Papagiorgis P, Oikonomakis I, Karapanagiotou I, et al. The impact of mmor location on the histopathologic expression of colorectal cancer. J BUON 2006; 11: 3 17-2 1.
5. Azzoni C, Bottarelli L, Campanini N, et al. Distinct molecular patterns based on proximal and distal sporadic colorectal cancer: Arguments for different mechanisms in the mmorigenesis. mt J Colorectal Dis 2007;22: 115-26.
6. Lindblom A. Different mechanisms in the mmorigenesis of proximal and distal colon cancers. Curr Opin Oncol 2001;13: 63-9.
7. Catalano T, Curia MC, Aceto G, et al. Mutations in the pS3 and Kiras genes, microsatellite instability and site of mmor origin in cob- rectal cancet Oncol Rep 2005;14: 62 5-31.
8. Li FY, Lai MD. Colorectal cancer, one entity or three. J Zbejiang Univ Sci B 2009;10: 2 19-29.
9. Grady WM, Carethers JM. Genomic and epigenetic instability in colorectal cancer pathogenesis. Gastroenterology 2008; 135: 1079-99.
10. Rampazzo E, Bertorelle R, Serra L, et al. Relationship between telomere shortening, genetic instability, and site of mmour origin in colorectal cancers. BrJ Cancer 2010;102: 1300-5.
11. Cukusic A, Skrobot Vidacek N, Sopta M, et al. Telomerase regulation at the crossroads of cell fate. Cytogenet Genome Res 2008;122: 263-72.
12. Allegra CJ, Parr AL, Wold LE, et al. hvestigation of the prognostic and predictive value of thymidylate synthase, p53, and Ki-67 in patients with locally advanced colon cancer. J Clin Oncol 2002;20: 1735-43.
13. Baretton GB, Diebold J, Christoforis G, et al. Apoptosis and immunohistochemical bcl-2 expression in colorectal adenomas and carcinomas. Aspects of carcinogenesis and prognostic significance. Cancer 1996;77: 255-64.
14. Rilska M, Collan \J, 0 Laine VJ, et al. The significance of mmor markers for proliferation and apoptosis in predicting survival in cob- rectal cancet Dis Colon Rectum 2005;48: 2197-208.
15. Blackburn ER. Switching and signaling at the telomere. Cell 2001; 106: 661-73
16. Satyanarayana A, Manns MP, Rudolph KL. Telomeres, telomerase and cancer: An endless search to target the ends. Cell Cycle 2004;3: 1138-50.
17. Cong YS, Wen J, Bacchetti S. The human telomerase catalytic subunit hTERT: organization of the gene and characterization of the promoter. Hum Mol Genet 1999;8: 137-42.
18. Wick M, Zubov D, Hagen G. Genomic organization and promoter characterization of the gene encoding the human telomerase reverse transcriptase (hTERT). Gene 1999;232: 97-106.
19. Nugent CI, Lundblad V. The telomerase reverse transcriptase: components and regulation. Genes Dev 1998;12: 1073-85.
20. Rosenberg R, Gertler R, Stricker D, et al. Telomere length and hTERT expression in patients with colorectal carcinoma. Recent Results Cancer Res 2003;162: 177-81.
21. Gertler R, Rosenberg R, Stricker D, et al. Telomere length and human telomerase reverse transcriptase expression as markers for progression and prognosis of colorectal carcinoma. J Clin Oncol 2004;22: 1807-14.
22. Tahara H, Yasui W, Tahara E, et al. Immuno-histochemical detection of human telomerase catalytic component, hTERT, in human colorectal tumor and non-tumor tissue sections. Oncogene 1999;18: 1561-7.
23. Kammori M, Kanauchi H, Nakamura K, et al. Demonstration of human telomerase reverse transcriptase in human colorectal carcin - omas by in situ hybridization. Int J Oncol 2002;20: 15-21.
24. Kim NW, Piatyszek MA, Prowse KR, et al. Specific association of human telomerase activity with immortal cells and cancer. Science 1994; 266: 2011-5.
25. Shay JW, Bacchetti S. A survey of telomerase activity in human cancer. Eur J Cancer 1997;33: 787-91.
26. de Kok JB, Ruers TJ, van Muijen GN, et al. Real-time quantification of human telomerase reverse transcriptase mRNA in tumors and healthy tissues. Clin Chem 2000;46: 313-8.
27. Nowak J, Januszkiewicz D, Lewandowski K, et al. Activity and expression of human telomerase in normal and malignant cells in gastric and colon cancer patients. Eur J Gastroenterol Hepatol 2003;15: 75-80.
28. Yasui W, Tahara E, Tahara H, et al. Immunohistochemical detection of human telomerase reverse transcriptase in normal mucosa and precancerous lesions of the stomach. Jpn J Cancer Res 1999;90: 589-95.
29. Yan P, Saraga EP, Bouzourene H, et al. Expression of telomerase genes correlates with telomerase activity in human colorectal carcinogenesis. J Pathol 2001;193: 21-6.
30. Boldrini L, Faviana P, Gisfredi S, et al. Evaluation of telomerase in the development and progression of colon cancer. Int J Mol Med 2002;10: 589-92.
31. Saleh S, Lam AK, Ho YH. Real-time PCR quantification of human telomerase reverse transcriptase (hTERT) in colorectal cancer. Pathology 2008;40: 25-30.
32. Niiyama H, Mizumoto K, Sato N, et al. Quantitative analysis of hTERT mRNA expression in colorectal cancer. Am J Gastroenterol 2001;96: 1895-900.
33. Gonzalo V, Petit A, Castellvi-Bel S, et al. Telomerase mRNA expression and immunohistochemical detection as a biomarker of malignant transformation in patients with inflammatory bowel disease. Gastroenterol Hepatol 2010;33: 288-96.
34. O'Sullivan JN, Bronner MP, Brentnall TA, et al. Chromosomal in - stabil ity in ulcerative colitis is related to telomere shortening. Nat Genet 2002;32: 280-4.
35. Risques RA, Lai LA, Brentnall TA, et al. Ulcerative colitis is a disease of accelerated colon aging: evidence from telomere attrition and DNA damage. Gastroenterology 2008;135: 410-8.
36. Yoshida R, Kiyozuka Y, Ichiyoshi H, et al. Change in telomerase activity during human colorectal carcinogenesis. Anticancer Res 1999;19: 2167-72.
37. Gertler R, Rosenberg R, Stricker D, et al. Prognostic potential of the telomerase subunit human telomerase reverse transcriptase in tumor tissue and nontumorous mucosa from patients with colorectal carcinoma. Cancer 2002;95: 2103-11.
38. Tatsumoto N, Hiyama E, Murakami Y, et al. High telomerase activity is an independent prognostic indicator of poor outcome in colorectal cancer. Clin Cancer Res 2000;6: 2696-701.
39. O'Sullivan J, Risques RA, Mandelson MT, et al. Telomere length in the colon declines with age: A relation to colorectal cancer? Cancer Epidemiol Biomarkers Prev 2006;15: 573-7.
40. Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012;487: 330-7.
41. Rudolph KL, Millard M, Bosenberg MW, et al. Telomere dysfunction and evolution of intestinal carcinoma in mice and humans. Nat Genet 2001;28: 155-9.
42. Gervaz P, Bucher P, Morel P. Two colons - two cancers: paradigm shift and clinical implications. J Surg Oncol 2004;88: 261-6.
43. Vousden KH, Lu X. Live or let die: the cell's response to p53. Nat Rev Cancer 2002;2: 594-604.
44. Miyashita T, Harigai M, Hanada M, et al. Identification of a p53- dependent negative response element in the bcl-2 gene. Cancer Res 1994;54: 3131-5.
45. Kusumoto M, Ogawa T, Mizumoto K, et al. Adenovirus-mediated p53 gene transduction inhibits telomerase activity independent of its effects on cell cycle arrest and apoptosis in human pancreatic cancer cells. Clin Cancer Res 1999;5: 2140-7.
46. Kanaya T, Kyo S, Hamada K, et al. Adenoviral expression of p53 represses telomerase activity through down-regulation of human telomerase reverse transcriptase transcription. Clin Cancer Res 2000;6: 1239-47.
47. Xu D, Wang Q, Gruber A, et al. Downregulation of telomerase reverse transcriptase mRNA expression by wild type p53 in human tumor cells. Oncogene 2000;19: 5123-33.
48. Stampfer MR, Garbe J, Nijjar T, et al. Loss of p53 function accelerates acquisition of telomerase activity in indefinite lifespan human mammary epithelial cell lines. Oncogene 2003;22: 5238-51.
49. Beliveau A, Yaswen P. Soothing the watchman: telomerase reduces the p53-dependent cellular stress response. Cell Cycle 2007;6: 1284-7.
50. Beitzinger M, Oswald C, Beinoraviciute-Kellner R, et al. Regulation of telomerase activity by the p53 family member p73. Oncogene 2006;25: 813-26.
51. Jin X, Beck S, Sohn YW, et al. Human telomerase catalytic subunit (hTERT) suppresses p53-mediated anti-apoptotic response via induction of basic fibroblast growth factor. Exp Mol Med 2010;42: 574-82.
52. Rahman R, Latonen L, Wiman KG. hTERT antagonizes p53-induced apoptosis independently of telomerase activity. Oncogene 2005;24: 1320-7.
53. Cao Y, Li H, Deb S, et al. TERT regulates cell survival independent of telomerase enzymatic activity. Oncogene 2002;21: 3130-8.
54. Boldrini L, Faviana P, Gisfredi S, et al. Regulation of telomerase and its hTERT messenger in colorectal cancer. Oncol Rep 2004;11: 395-400.
55. Pantic M, Zimmermann S, El Daly H, et al. Telomere dysfunction and loss of p53 cooperate in defective mitotic segregation of chromosomes in cancer cells. Oncogene 2006;25: 4413-20.
56. Risques RA, Lai LA, Himmetoglu C, et al. Ulcerative colitisassociated colorectal cancer arises in a field of short telomeres, senescence, and inflammation. Cancer Res 2011;71: 1669-79.